Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H23NO3S |
Molecular Weight | 333.445 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC3(COC1=CC=C(CC2SC(=O)NC2=O)C=C1)CCCCC3
InChI
InChIKey=YZFWTZACSRHJQD-UHFFFAOYSA-N
InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)
Molecular Formula | C18H23NO3S |
Molecular Weight | 333.445 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Ciglitazone, 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione, is a hypoglycemic agent and a thiazolidenedione derivative. Ciglitazone binds to the PPAR gamma receptor and possesses agonist activity. This drug was in clinical trials in Japan for the treatment Diabetes mellitus, but that study has been discontinued. Ciglitazone was able to decrease the production of vascular endothelial growth factor (VEGF) in an in vitro human granulosa cell model. That result together with the pivotal role of VEGF in ovarian hyperstimulation syndrome suggests that ciglitazone may have a high potential as a therapeutic agent.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19923366
Curator's Comment: # Takeda
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P37231|||Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22609261 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: DOI: 10.1016/j.jtumed.2016.02.001 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3986302 |
125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIGLITAZONE plasma | Canis lupus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3986302 |
125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIGLITAZONE plasma | Canis lupus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
138 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3986302 |
125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIGLITAZONE plasma | Canis lupus population: HEALTHY age: ADULT sex: MALE food status: FED |
|
93 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3986302 |
125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIGLITAZONE plasma | Canis lupus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. | 1998 Dec 3 |
|
Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. | 1999 Mar 26 |
|
Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line. | 2000 Oct |
|
Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. | 2001 Apr 13 |
|
Arylhydrocarbon receptor (AhR) is involved in negative regulation of adipose differentiation in 3T3-L1 cells: AhR inhibits adipose differentiation independently of dioxin. | 2001 Aug |
|
Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. | 2001 Jun 22 |
|
Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. | 2001 May |
|
Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. | 2002 Feb |
|
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. | 2002 Jul |
|
Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929. | 2002 Jul 15 |
|
Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. | 2002 Jun |
|
Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. | 2002 Jun 21 |
|
Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. | 2003 Jan 15 |
|
PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. | 2003 Jul |
|
15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism. | 2003 Mar 7 |
|
Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. | 2004 Oct |
|
Effect of peroxisome proliferator-activated receptor-gamma ligands on the expression of retinoic acid-inducible gene-I in endothelial cells stimulated with lipopolysaccharide. | 2005 Dec |
|
Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. | 2005 May |
|
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. | 2005 May 12 |
|
Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. | 2005 May 15 |
|
Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition. | 2006 Aug |
|
Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. | 2006 Feb 28 |
|
Involvement of PPARgamma in oxidative stress-mediated prostaglandin E(2) production in SZ95 human sebaceous gland cells. | 2006 Jan |
|
Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors. | 2007 May |
|
Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. | 2007 May |
|
Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. | 2007 May |
|
Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. | 2007 Oct 1 |
|
Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation. | 2007 Sep |
|
Nuclear receptor agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture. | 2008 Mar |
|
Effects of the mango components mangiferin and quercetin and the putative mangiferin metabolite norathyriol on the transactivation of peroxisome proliferator-activated receptor isoforms. | 2008 May 14 |
|
Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. | 2009 Apr |
|
Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. | 2010 Apr |
|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | 2010 Dec |
|
Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands. | 2010 Nov 16 |
|
Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. | 2011 Aug |
|
Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. | 2011 Aug |
|
The use of rat lens explant cultures to study the mechanism of drug-induced cataractogenesis. | 2012 Mar |
|
Fenofibrate suppresses melanogenesis in B16-F10 melanoma cells via activation of the p38 mitogen-activated protein kinase pathway. | 2013 Oct 5 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://adisinsight.springer.com/drugs/800004145
for Diabetes mellitus in Japan
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22609261
Human middle ear epithelial cell lines (HMEECs) with or without ciglitazone pre-treatment were exposed to cigarette smoke solution (CSS) in order to induce the inflammatory response. The suppressive effect of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2(COX-2), were evaluated using real-time polymerase chain reaction and Western blotting. Stimulation with CSS at 40 μg/ml for 6 h resulted in a 4.1-fold increase in the expression of TNF-α mRNA in the HMEECs. CSS-induced up-regulation of TNF-α mRNA was decreased by more than 2.8-fold in cells pre-treated with ciglitazone. The up-regulation of COX-2 mRNA and increased COX-2 protein expression induced by CSS were also inhibited by more than 3.7-fold with ciglitazone pre-treatment.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:55:50 UTC 2023
by
admin
on
Sat Dec 16 15:55:50 UTC 2023
|
Record UNII |
U8QXS1WU8G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98241
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB09201
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
U8QXS1WU8G
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
SUB06260MIG
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
100000081290
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
CIGLITAZONE
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
T-124
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
2750
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
C039671
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
DTXSID0040757
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
C72726
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
5364
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
CHEMBL7002
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
64227
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY | |||
|
74772-77-3
Created by
admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE |
|
||
|
TARGET -> AGONIST |
Binding Assay
IC50
|
||
|
ENANTIOMER -> RACEMATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|